These findings highlight the importance of further research on the molecular mechanisms underlying PD-1 and CTLA-4 dysregulation, as well as the potential role for these molecules in targeted therapies and personalized treatment strategies for HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.